These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 31256288)
41. PET imaging for a very early detection of rapid eye movement sleep behaviour disorder and Parkinson's disease - A model-based cost-effectiveness analysis. Fezeu F; Jbara OF; Jbarah A; Choucha A; De Maria L; Ciaglia E; De Simone M; Samnick S Clin Neurol Neurosurg; 2024 Aug; 243():108404. PubMed ID: 38944021 [TBL] [Abstract][Full Text] [Related]
42. Atypical clinical presentation of pathologically proven Parkinson's disease: The role of Parkinson's disease related metabolic pattern. Rus T; Tomše P; Jensterle L; Ležaić L; Stokin CL; Popović M; Tang CC; Eidelberg D; Pirtošek Z; Trošt M Parkinsonism Relat Disord; 2020 Sep; 78():1-3. PubMed ID: 32659618 [TBL] [Abstract][Full Text] [Related]
43. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease. Thobois S; Guillouet S; Broussolle E Neurophysiol Clin; 2001 Oct; 31(5):321-40. PubMed ID: 11817273 [TBL] [Abstract][Full Text] [Related]
44. Severe Brain Metabolic Decreases Associated with REM Sleep Behavior Disorder in Dementia with Lewy Bodies. Iaccarino L; Marelli S; Iannaccone S; Magnani G; Ferini-Strambi L; Perani D J Alzheimers Dis; 2016 Apr; 52(3):989-97. PubMed ID: 27060952 [TBL] [Abstract][Full Text] [Related]
45. Functional imaging in pre-motor Parkinson's disease. Arnaldi D; Morbelli S; Picco A; Ferrara M; Buschiazzo A; Famà F; De Carli F; Nobili F Q J Nucl Med Mol Imaging; 2014 Dec; 58(4):366-75. PubMed ID: 25366709 [TBL] [Abstract][Full Text] [Related]
46. The effects of image reconstruction algorithms on topographic characteristics, diagnostic performance and clinical correlation of metabolic brain networks in Parkinson's disease. Tomše P; Peng S; Pirtošek Z; Zaletel K; Dhawan V; Eidelberg D; Ma Y; Trošt M Phys Med; 2018 Aug; 52():104-112. PubMed ID: 30139598 [TBL] [Abstract][Full Text] [Related]
47. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment. Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056 [TBL] [Abstract][Full Text] [Related]
48. Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease. Kuhl DE; Metter EJ; Riege WH; Markham CH Ann Neurol; 1984; 15 Suppl():S119-25. PubMed ID: 6234856 [TBL] [Abstract][Full Text] [Related]
49. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. Feigin A; Leenders KL; Moeller JR; Missimer J; Kuenig G; Spetsieris P; Antonini A; Eidelberg D J Nucl Med; 2001 Nov; 42(11):1591-5. PubMed ID: 11696626 [TBL] [Abstract][Full Text] [Related]
50. The value of putaminal diffusion imaging versus 18-fluorodeoxyglucose positron emission tomography for the differential diagnosis of the Parkinson variant of multiple system atrophy. Baudrexel S; Seifried C; Penndorf B; Klein JC; Middendorp M; Steinmetz H; Grünwald F; Hilker R Mov Disord; 2014 Mar; 29(3):380-7. PubMed ID: 24243813 [TBL] [Abstract][Full Text] [Related]
51. Brain metabolic correlates of fatigue in Parkinson's disease: a PET study. Zhang L; Li T; Yuan Y; Tong Q; Jiang S; Wang M; Wang J; Ding J; Xu Q; Zhang K Int J Neurosci; 2018 Apr; 128(4):330-336. PubMed ID: 28918694 [TBL] [Abstract][Full Text] [Related]
52. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting. Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117 [TBL] [Abstract][Full Text] [Related]
53. Metabolic imaging and plasticity. Ko JH; Strafella AP Handb Clin Neurol; 2022; 184():121-132. PubMed ID: 35034729 [TBL] [Abstract][Full Text] [Related]
54. Neuroimaging markers of motor and nonmotor features of Parkinson's disease: an 18f fluorodeoxyglucose positron emission computed tomography study. Huang C; Ravdin LD; Nirenberg MJ; Piboolnurak P; Severt L; Maniscalco JS; Solnes L; Dorfman BJ; Henchcliffe C Dement Geriatr Cogn Disord; 2013; 35(3-4):183-96. PubMed ID: 23445555 [TBL] [Abstract][Full Text] [Related]
55. Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. Massa F; Arnaldi D; De Cesari F; Girtler N; Brugnolo A; Grazzini M; Bauckneht M; Meli R; Morbelli S; Pardini M; Sambuceti G; De Carli F; Tiraboschi P; Nobili F Neurobiol Aging; 2019 Apr; 76():9-17. PubMed ID: 30611093 [TBL] [Abstract][Full Text] [Related]
57. A preoperative metabolic marker of parkinsonian apathy following subthalamic nucleus stimulation. Gesquière-Dando A; Guedj E; Loundou A; Carron R; Witjas T; Fluchère F; Delfini M; Mundler L; Regis J; Azulay JP; Eusebio A Mov Disord; 2015 Nov; 30(13):1767-76. PubMed ID: 26228098 [TBL] [Abstract][Full Text] [Related]
58. [Functional neuroimaging in movement disorders]. Borbély K Orv Hetil; 2001 Oct; 142(43):2347-55. PubMed ID: 11760452 [TBL] [Abstract][Full Text] [Related]
59. The scintigraphic evaluation of Huntington's disease and other movement disorders using single photon emission computed tomography perfusion brain scans. Nagel JS; Ichise M; Holman BL Semin Nucl Med; 1991 Jan; 21(1):11-23. PubMed ID: 1825359 [TBL] [Abstract][Full Text] [Related]
60. Cognitive profile and 18F-fluorodeoxyglucose PET study in LRRK2-related Parkinson's disease. De Rosa A; Peluso S; De Lucia N; Russo P; Annarumma I; Esposito M; Manganelli F; Brunetti A; De Michele G; Pappatà S Parkinsonism Relat Disord; 2018 Feb; 47():80-83. PubMed ID: 29249679 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]